HK Stock Market Move | INNOGEN-B (02591) fell by over 13%, after a cumulative increase of 50% in the past two weeks. It officially entered the Hong Kong Stock Connect today.

INNOGEN-B (02591) fell by more than 13%, after a cumulative increase of 50% in the previous two weeks. As of the publication, it dropped by 13.64% to HK$ 38, with a trading volume of 30.31 million Hong Kong dollars. On the news front, the Shanghai and Shenzhen stock exchanges announced that due to the component stock adjustment of the Hang Seng Composite Mid Cap Index, the list of stocks eligible for trading through the Hong Kong Stock Connect has been adjusted. Yinnuo Medicine has been added to the list, effective from December 8, 2025. In addition, Yinnuo Medicine announced that its independently developed long-acting GLP-1 receptor agonist, Exenatide Alpha (Yinuoqin), has been officially included in the National Medical Insurance Drug Catalogue for 2025, and will be implemented concurrently with the new catalogue from January 1, 2026.